GlassScriptPhysician profile
Kimberley Lingler
NPI 1255517124
$2,226.81
in general payments reported to CMS, 2019-2025
26 companies · $136 in 2025
The $136 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $140 · 2020: $50.36 · 2021: $337 · 2022: $518 · 2023: $780 · 2024: $265 · 2025: $136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,180.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $464.84 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $256.88 | 2021-2025 | Freestyle Libre 3 |
| Amgen INC. | $199.62 | 2021-2024 | Otezla, Prolia, Evenity |
| Abbvie INC. | $180.63 | 2022-2023 | |
| Lilly USA, LLC | $135.82 | 2019-2025 | Mounjaro, Trulicity, Kisunla |
| Exact Sciences Corporation | $125.41 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boston Scientific Corporation | $105.73 | 2022-2024 | Watchman Flx, Wavewriter Alpha Prime 16 |
| Biohaven Pharmaceutical Holding Company LTD. | $80.52 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $62.08 | 2022-2023 | Rexulti |
| Sanofi-Aventis U.S. LLC | $60.18 | 2021-2022 | |
| Pfizer INC. | $56.94 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $55.69 | 2022 | |
| Merck Sharp & Dohme LLC | $53.94 | 2019-2023 | Belsomra, Dificid |
| Biohaven Pharmaceuticals, INC. | $51.10 | 2021 | |
| Philips North America LLC | $49.35 | 2024-2025 | Ambulatory Monitoring & Diagnostics Undivided, (Ck6) Holter |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $47.54 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.44 | 2021-2022 | |
| Glaxosmithkline, LLC. | $34.42 | 2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $32.40 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $25.44 | 2019-2020 | |
| Dexcom, INC. | $23.73 | 2024 | Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $21.18 | 2023 | Inspire |
| Cequr Corporation | $16.92 | 2025 | Cequr Simplicity |
| Ultragenyx Pharmaceutical INC. | $14.52 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.17 | 2023 | |
| Janssen Pharmaceuticals, INC | $11.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberley Lingler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.